183 related articles for article (PubMed ID: 29192354)
1. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Cho H; Yoo C; Kim KP; Jeong JH; Kang J; Chang HM; Lee SS; Park DH; Song TJ; Lee SK; Kim MH; Lee HC; Lim YS; Kim KM; Shim JH; Hwang S; Song GW; Moon DB; Lee JH; Lee YJ; Ryoo BY
Invest New Drugs; 2018 Jun; 36(3):496-502. PubMed ID: 29192354
[TBL] [Abstract][Full Text] [Related]
2. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
[TBL] [Abstract][Full Text] [Related]
6. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
7. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
Lee SY; Kim HS; Choi YJ; Park KH; Shin SW; Kim YH; Tae Kim S
Am J Ther; 2016; 23(6):e1449-e1455. PubMed ID: 25285672
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
10. Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma.
Okuno M; Ebata T; Yokoyama Y; Igami T; Sugawara G; Mizuno T; Yamaguchi J; Nagino M
J Hepatobiliary Pancreat Sci; 2016 Oct; 23(10):636-642. PubMed ID: 27474781
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
12. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
Asama H; Suzuki R; Takagi T; Sugimoto M; Konno N; Watanabe K; Nakamura J; Kikuchi H; Takasumi M; Sato Y; Irie H; Hikichi T; Ohira H
Mol Clin Oncol; 2018 Oct; 9(4):408-414. PubMed ID: 30233794
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
Salimon M; Prieux-Klotz C; Tougeron D; Hautefeuille V; Caulet M; Gournay J; Matysiak-Budnik T; Bennouna J; Tiako Meyo M; Lecomte T; Zaanan A; Touchefeu Y
Br J Cancer; 2018 Feb; 118(3):325-330. PubMed ID: 29169182
[TBL] [Abstract][Full Text] [Related]
16. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
17. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
[TBL] [Abstract][Full Text] [Related]
18. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Maßmann M; Treckmann J; Markus P; Schumacher B; Albers D; Ting S; Mende B; Roehrle J; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Schmid KW; Baba H; Siveke JT; Paul A; Schildhaus HU; Schuler M; Wiesweg M; Kasper S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5085-5094. PubMed ID: 36334155
[TBL] [Abstract][Full Text] [Related]
19. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]